PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: PET based Raditherapy boost.
- Who it may be relevant to
- Registry conditions: Small Cell Lung Carcinoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Germany
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prospective PET-guided Radiotherapy for Patients With Small Cell Lung Cancer.
Overview
There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF
Detailed description
The main objective of this study is to determine whether patients with SCLC who have a metabolically active residual tumor in the fluorodeoxyglucose (FDG) PET/CT scan after two to three cycles of induction chemotherapy have a similarly low local recurrence rate with higher dose. There is a prospective risk-adapted evaluation of the optimal dose of radiotherapy for definitive radiotherapy of locally advanced small cell lung cancer within the corridor recommended as standard therapy according to the current interdisciplinary S3 guideline of the German Cancer Society/Cancer Aid/AWMF. Allocation to PET boost, if confirmed vital tumor rest by PET CT and biopsy.
Interventions
- Radiation PET based Raditherapy boost
An Interim PET CT will be performed. If there is residual vital tumor, a higher radiation dose will be applied.
Primary outcome measures
- Local recurrence free survival [Time frame: 2 months to 5 years]
- Distant recurrence free survival [Time frame: 2 months to 5 years]
- Overall survival [Time frame: 2 months to 5 years]
Eligibility criteria
Inclusion criteria
- Histopathologic confirmation
- Limited disease
Exclusion criteria
- Other histology than small cell lung cancer
- Further tumor diagnosis
- ECOG 3 or worse
- Extensive disease
- stage IV
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Germany · 1 center
- University Hospital Essen — Essen
Identifiers
NCT: NCT06247163 · 23-11560-BO